Clinical Trial Update: Zalutumumab in Non-curable Patients With SCCHN [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for zalutumumab in non-curable head and neck squamous cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Zalutumumab (zalutumumab)

Snippet

Sponsor: Genmab | Conditions: Head and Neck Cancer, Squamous Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-08-27